

# Andrew A Nierenberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11256873/publications.pdf>

Version: 2024-02-01

226  
papers

31,188  
citations

7251

80  
h-index

5102

172  
g-index

229  
all docs

229  
docs citations

229  
times ranked

19456  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a model to predict psychotherapy response for depression among Veterans. <i>Psychological Medicine</i> , 2023, 53, 3591-3600.	2.7	4
2	Association of Lithium Treatment With the Risk of Osteoporosis in Patients With Bipolar Disorder. <i>JAMA Psychiatry</i> , 2022, 79, 454.	6.0	20
3	Strategies and foundations for scientific discovery in longitudinal studies of bipolar disorder. <i>Bipolar Disorders</i> , 2022, 24, 499-508.	1.1	15
4	Convergence between behavioral, neural, and self-report measures of cognitive control: The Frontal Systems Behavior Scale in bipolar disorder. <i>Journal of Psychiatric Research</i> , 2022, 150, 317-323.	1.5	1
5	The relationship between suicidal thoughts and well-being among individuals with a history of depression and cardiovascular risk. <i>Psychiatry Research Communications</i> , 2022, 2, 100059.	0.2	1
6	Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: Findings from the Bipolar CHOICE and LiTMUS trials. <i>Depression and Anxiety</i> , 2021, 38, 114-123.	2.0	5
7	A surrogate measure for patient reported symptom remission in administrative data. <i>BMC Psychiatry</i> , 2021, 21, 121.	1.1	4
8	Psychotic symptoms during bipolar depressive episodes and suicidal ideation. <i>Journal of Affective Disorders</i> , 2021, 282, 1241-1246.	2.0	4
9	Response and remission rates during 24 weeks of mood-stabilizing treatment for bipolar depression depending on early non-response. <i>Psychiatry Research</i> , 2021, 305, 114194.	1.7	1
10	Dimensional Neural Markers of Affective Processing in Bipolar Disorder. <i>Psychiatry Research</i> , 2021, 307, 114304.	1.7	0
11	Bipolar disorders. <i>Lancet, The</i> , 2020, 396, 1841-1856.	6.3	419
12	20-Year Trends in the Pharmacologic Treatment of Bipolar Disorder by Psychiatrists in Outpatient Care Settings. <i>American Journal of Psychiatry</i> , 2020, 177, 706-715.	4.0	133
13	Clinical Correlates of False Positive Assignment in Bipolar Screening Measures Across Psychiatric Diagnoses among Patients without Bipolar Disorder. <i>Psychiatry Investigation</i> , 2020, 17, 1118-1125.	0.7	2
14	Trajectories of Psychiatric Disorders and the Challenge of Relapse and Recurrence: A Network Perspective. <i>Psychiatric Annals</i> , 2020, 50, 134-135.	0.1	0
15	Beyond evidence-based treatment of bipolar disorder: Rational pragmatic approaches to management. <i>Bipolar Disorders</i> , 2019, 21, 650-659.	1.1	19
16	Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors. <i>Journal of Affective Disorders</i> , 2019, 257, 17-22.	2.0	26
17	Bipolar depression and suicidal ideation: Moderators and mediators of a complex relationship. <i>Journal of Affective Disorders</i> , 2019, 259, 164-172.	2.0	13
18	Predictive modeling for response to lithium and quetiapine in bipolar disorder. <i>Bipolar Disorders</i> , 2019, 21, 428-436.	1.1	15

#	ARTICLE	IF	CITATIONS
19	Objective smartphone data as a potential diagnostic marker of bipolar disorder. Australian and New Zealand Journal of Psychiatry, 2019, 53, 171-172.	1.3	1
20	Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale. Journal of Affective Disorders, 2019, 246, 126-131.	2.0	11
21	Statin treatment and the risk of depression. Journal of Affective Disorders, 2019, 246, 706-715.	2.0	31
22	Tachyphylaxis in major depressive disorder: A review of the current state of research. Journal of Affective Disorders, 2019, 245, 488-497.	2.0	23
23	Adjunctive Nutrition Therapy for Depression. Psychiatric Annals, 2019, 49, 21-25.	0.1	6
24	Substance use comorbidity in bipolar disorder: A qualitative review of treatment strategies and outcomes. American Journal on Addictions, 2018, 27, 188-201.	1.3	28
25	Treatment outcomes of acute bipolar depressive episode with psychosis. Depression and Anxiety, 2018, 35, 402-410.	2.0	9
26	Decreased activation and subsyndromal manic symptoms predict lower remission rates in bipolar depression. Australian and New Zealand Journal of Psychiatry, 2018, 52, 994-1002.	1.3	3
27	Forecasting depressive relapse in Bipolar Disorder from clinical data. , 2018, , .		5
28	MoodNetwork. Medical Care, 2018, 56, S48-S52.	1.1	13
29	Applying Association Rules to Study Bipolar Disorder and Premenstrual Dysphoric Disorder Comorbidity. , 2018, , .		3
30	The impact of substance use disorders on recovery from bipolar depression: Results from the Systematic Treatment Enhancement Program for Bipolar Disorder psychosocial treatment trial. Australian and New Zealand Journal of Psychiatry, 2018, 52, 847-855.	1.3	9
31	Intrinsic functional neurocircuitry associated with treatment response to transdiagnostic CBT in bipolar disorder with anxiety. Journal of Affective Disorders, 2018, 238, 383-391.	2.0	13
32	Innovating Innovation. Psychiatric Annals, 2018, 48, 262-262.	0.1	0
33	Dialectical Behavior Therapy Group Skills Training for Bipolar Disorder. Behavior Therapy, 2017, 48, 557-566.	1.3	46
34	Bipolar mixed features " Results from the comparative effectiveness for bipolar disorder (Bipolar) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.0	10
35	Do Sleep Disturbances Predict or Moderate the Response to Psychotherapy in Bipolar Disorder?. Journal of Nervous and Mental Disease, 2017, 205, 196-202.	0.5	5
36	Transdiagnostic treatment of bipolar disorder and comorbid anxiety using the Unified Protocol for Emotional Disorders: A pilot feasibility and acceptability trial. Journal of Affective Disorders, 2017, 219, 209-221.	2.0	44

#	ARTICLE	IF	CITATIONS
37	Poor quality of life and functioning in bipolar disorder. <i>International Journal of Bipolar Disorders</i> , 2017, 5, 10.	0.8	63
38	Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 555-561.	0.7	9
39	L-Methylfolate For Bipolar I depressive episodes: An open trial proof-of-concept registry. <i>Journal of Affective Disorders</i> , 2017, 207, 429-433.	2.0	18
40	Testing for clinical inertia in medication treatment of bipolar disorder. <i>Journal of Affective Disorders</i> , 2016, 205, 13-19.	2.0	4
41	SPECIFIC MOOD SYMPTOMS CONFER RISK FOR SUBSEQUENT SUICIDAL IDEATION IN BIPOLAR DISORDER WITH AND WITHOUT SUICIDE ATTEMPT HISTORY: MULTI-WAVE DATA FROM STEP-BD. <i>Depression and Anxiety</i> , 2016, 33, 464-472.	2.0	27
42	Affective instability and the course of bipolar depression: Results from the STEP-BD randomised controlled trial of psychosocial treatment. <i>British Journal of Psychiatry</i> , 2016, 208, 352-358.	1.7	21
43	The Effect of Concomitant Treatment With SSRIs and Statins: A Population-Based Study. <i>American Journal of Psychiatry</i> , 2016, 173, 807-815.	4.0	63
44	Tracking medication changes to assess outcomes in comparative effectiveness research: A bipolar CHOICE study. <i>Journal of Affective Disorders</i> , 2016, 205, 159-164.	2.0	7
45	A cluster analytic approach to identifying predictors and moderators of psychosocial treatment for bipolar depression: Results from STEP-BD. <i>Journal of Affective Disorders</i> , 2016, 203, 152-157.	2.0	9
46	Medical burden, body mass index and the outcome of psychosocial interventions for bipolar depression. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 667-677.	1.3	16
47	Patient perceptions of physical health and bipolar symptoms: The intersection of mental and physical health. <i>Journal of Affective Disorders</i> , 2016, 189, 203-206.	2.0	18
48	A latent class analysis of parental bipolar disorder: Examining associations with offspring psychopathology. <i>Psychiatry Research</i> , 2015, 230, 314-322.	1.7	5
49	Getting to wellness: The potential of the athletic model of marginal gains for the treatment of bipolar disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 1207-1214.	1.3	21
50	Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar <sc>CHOICE</sc>). <i>Bipolar Disorders</i> , 2015, 17, 212-223.	1.1	77
51	Effectiveness Trials in Bipolar Disorders. , 2015, , 23-28.		0
52	Family functioning in the context of parental bipolar disorder: Associations with offspring age, sex, and psychopathology.. <i>Journal of Family Psychology</i> , 2015, 29, 108-118.	1.0	17
53	Complexity of Illness and Adjunctive Benzodiazepine Use in Outpatients With Bipolar I or II Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 68-74.	0.7	18
54	A clinical measure of suicidal ideation, suicidal behavior, and associated symptoms in bipolar disorder: Psychometric properties of the Concise Health Risk Tracking Self-Report (CHRT-SR). <i>Journal of Psychiatric Research</i> , 2015, 71, 126-133.	1.5	32

#	ARTICLE	IF	CITATIONS
55	The effect of personalized guideline-concordant treatment on quality of life and functional impairment in bipolar disorder. <i>Journal of Affective Disorders</i> , 2014, 169, 144-148.	2.0	15
56	EARLY RISK FACTORS FOR PSYCHOPATHOLOGY IN OFFSPRING OF PARENTS WITH BIPOLAR DISORDER: THE ROLE OF OBSTETRIC COMPLICATIONS AND MATERNAL COMORBID ANXIETY. <i>Depression and Anxiety</i> , 2014, 31, 583-590.	2.0	12
57	EPIDEMIOLOGY AND COURSE OF UNIPOLAR MANIA: RESULTS FROM THE NATIONAL EPIDEMIOLOGIC SURVEY ON ALCOHOL AND RELATED CONDITIONS (NESARC). <i>Depression and Anxiety</i> , 2014, 31, 746-755.	2.0	18
58	Clinical applications of herbal medicines for anxiety and insomnia; targeting patients with bipolar disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2014, 48, 705-715.	1.3	22
59	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. <i>American Journal of Psychiatry</i> , 2013, 170, 1249-1262.	4.0	579
60	SMOKING AND SUICIDALITY IN SUBJECTS WITH BIPOLAR DISORDER: RESULTS FROM THE NATIONAL EPIDEMIOLOGIC SURVEY ON ALCOHOL AND RELATED CONDITIONS (NESARC). <i>Depression and Anxiety</i> , 2013, 30, n/a-n/a.	2.0	14
61	Nutrient-Based Therapies for Bipolar Disorder: A Systematic Review. <i>Psychotherapy and Psychosomatics</i> , 2013, 82, 10-19.	4.0	46
62	Extreme attributions predict transition from depression to mania or hypomania in bipolar disorder. <i>Journal of Psychiatric Research</i> , 2013, 47, 1329-1336.	1.5	22
63	Association Between Therapeutic Alliance, Care Satisfaction, and Pharmacological Adherence in Bipolar Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 343-350.	0.7	37
64	One-carbon metabolism and bipolar disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 1013-1018.	1.3	31
65	Increase in Work Productivity of Depressed Individuals With Improvement in Depressive Symptom Severity. <i>American Journal of Psychiatry</i> , 2013, 170, 633-641.	4.0	104
66	Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 26-42.	1.3	61
67	Clinical and Sociodemographic Characteristics Associated with Suicidal Ideation in Depressed Outpatients. <i>Canadian Journal of Psychiatry</i> , 2013, 58, 113-122.	0.9	35
68	Conditional Probability of Response or Nonresponse of Placebo Compared With Antidepressants or St John's Wort in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 827-830.	0.7	3
69	Extreme Attributions Predict the Course of Bipolar Depression. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 249-255.	1.1	21
70	Sleep disturbance in euthymic bipolar patients. <i>Journal of Psychopharmacology</i> , 2012, 26, 1108-1112.	2.0	104
71	Transdiagnostic Treatment of Bipolar Disorder and Comorbid Anxiety With the Unified Protocol: A Clinical Replication Series. <i>Behavior Modification</i> , 2012, 36, 482-508.	1.1	56
72	Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 1387-1399.	1.0	21

#	ARTICLE	IF	CITATIONS
73	Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. <i>CNS Spectrums</i> , 2012, 17, 76-86.	0.7	15
74	Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study. <i>Focus (American Psychiatric Publishing)</i> , 2012, 10, 492-505.	0.4	1
75	Mindfulness-Based Cognitive Therapy for Nonremitted Patients with Bipolar Disorder. <i>CNS Neuroscience and Therapeutics</i> , 2012, 18, 133-141.	1.9	99
76	An exploratory study of combination buspirone and melatonin SR in Major Depressive Disorder (MDD): A possible role for neurogenesis in drug discovery. <i>Journal of Psychiatric Research</i> , 2012, 46, 1553-1563.	1.5	52
77	Cumulative morbidity and prognostic staging of illness in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). <i>Australian and New Zealand Journal of Psychiatry</i> , 2012, 46, 1058-1067.	1.3	82
78	Customization in prescribing for bipolar disorder. <i>Health Economics (United Kingdom)</i> , 2012, 21, 653-668.	0.8	8
79	A critical review of pharmacotherapy for major depressive disorder. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 1417-1431.	1.0	54
80	Residual Symptoms in Depressed Outpatients Who Respond by 50% But Do Not Remit to Antidepressant Medication. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 180-186.	0.7	166
81	The treatment of minor depression with St. John's Wort or citalopram: Failure to show benefit over placebo. <i>Journal of Psychiatric Research</i> , 2011, 45, 931-941.	1.5	48
82	Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: A CO-MED report. <i>Journal of Affective Disorders</i> , 2011, 133, 467-476.	2.0	45
83	Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. <i>Depression and Anxiety</i> , 2011, 28, 137-144.	2.0	73
84	Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study. <i>American Journal of Psychiatry</i> , 2011, 168, 689-701.	4.0	329
85	Mindfulness-Based Cognitive Therapy for Bipolar Disorder. <i>Journal of Psychiatric Practice</i> , 2011, 17, 410-419.	0.3	65
86	Longitudinal Follow-Up of Bipolar Disorder in Women With Premenstrual Exacerbation: Findings From STEP-BD. <i>American Journal of Psychiatry</i> , 2011, 168, 386-394.	4.0	53
87	A 32-Year-Old Male with Mania, Leg Pain, Migraines. <i>Psychiatric Annals</i> , 2011, 41, 363-366.	0.1	0
88	Linkage disequilibrium mapping of the chromosome 6q21 bipolar I disorder susceptibility locus. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 29-37.	1.1	9
89	Do atypical features affect outcome in depressed outpatients treated with citalopram?. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 15.	1.0	50
90	Comparisons of the Efficacy and Tolerability of Extended-Release Venlafaxine, Mirtazapine, and Paroxetine in Treatment-Resistant Depression. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 357-364.	0.7	48

#	ARTICLE	IF	CITATIONS
91	The influence of menopause status and postmenopausal use of hormone therapy on presentation of major depression in women. <i>Menopause</i> , 2010, 17, 828-839.	0.8	47
92	Something Borrowed, Something Blue: Why is Bipolar Disorder an Orphan?. <i>CNS Spectrums</i> , 2010, 15, 15-16.	0.7	0
93	Impact of Substance Use Disorders on Recovery From Episodes of Depression in Bipolar Disorder Patients: Prospective Data From the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). <i>American Journal of Psychiatry</i> , 2010, 167, 289-297.	4.0	103
94	RESEARCH: Cognitive Rehabilitation for Bipolar Disorder: An Open Trial for Employed Patients with Residual Depressive Symptoms. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 298-307.	1.9	171
95	A Critical Appraisal of Treatments for Bipolar Disorder. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2010, 12, 23-29.	0.6	10
96	Uncertainty and Practical Reasoning in Clinical Psychiatry and Neuropsychiatry. <i>CNS Spectrums</i> , 2009, 14, 284-285.	0.7	7
97	Tachyphylaxis after Repeated Antidepressant Drug Exposure in Patients with Recurrent Major Depressive Disorder. <i>Neuropsychobiology</i> , 2009, 59, 227-233.	0.9	34
98	Effectiveness Study of Venlafaxine-XR Combined with Aripiprazole for Chronic or Recurrent Major Depressive Disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2009, 43, 956-967.	1.3	9
99	Low-Dose Buspirone, Melatonin and Low-Dose Bupropion Added to Mood Stabilizers for Severe Treatment-Resistant Bipolar Depression. <i>Psychotherapy and Psychosomatics</i> , 2009, 78, 391-393.	4.0	15
100	Can Phase III Trial Results of Antidepressant Medications Be Generalized to Clinical Practice? A STAR*D Report. <i>American Journal of Psychiatry</i> , 2009, 166, 599-607.	4.0	209
101	Manic Symptoms During Depressive Episodes in 1,380 Patients With Bipolar Disorder: Findings From the STEP-BD. <i>American Journal of Psychiatry</i> , 2009, 166, 173-181.	4.0	263
102	What predicts attrition in second step medication treatments for depression?: a STAR*D Report. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 459.	1.0	69
103	Income and attrition in the treatment of depression: a STAR*D report. <i>Depression and Anxiety</i> , 2009, 26, 622-633.	2.0	44
104	Lessons from STEP-BD for the treatment of bipolar depression. <i>Depression and Anxiety</i> , 2009, 26, 106-109.	2.0	16
105	Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR*D trial. <i>Depression and Anxiety</i> , 2009, 26, 612-621.	2.0	28
106	Retrospective age at onset of bipolar disorder and outcome during two-year follow-up: results from the STEP-BD study. <i>Bipolar Disorders</i> , 2009, 11, 391-400.	1.1	229
107	Cigarette smoking is associated with suicidality in bipolar disorder. <i>Bipolar Disorders</i> , 2009, 11, 766-771.	1.1	50
108	Association study of 21 circadian genes with bipolar I disorder, schizoaffective disorder, and schizophrenia. <i>Bipolar Disorders</i> , 2009, 11, 701-710.	1.1	133



#	ARTICLE	IF	CITATIONS
109	Stability of symptoms across major depressive episodes in bipolar disorder. <i>Bipolar Disorders</i> , 2009, 11, 867-875.	1.1	17
110	GABAB Receptors, Schizophrenia and Sleep Dysfunction. <i>CNS Drugs</i> , 2009, PAP, 627-47.	2.7	220
111	Galantamineâ€œER For Cognitive Dysfunction In Bipolar Disorder and Correlation with Hippocampal Neuronal Viability: A Proofâ€œofâ€œConcept Study. <i>CNS Neuroscience and Therapeutics</i> , 2009, 15, 309-319.	1.9	41
112	Measuring Outcomes Makes Good Sense. <i>Psychiatric Services</i> , 2009, 60, 112-112.	1.1	7
113	Primary Versus Specialty Care Outcomes for Depressed Outpatients Managed with Measurement-Based Care: Results from STAR*D. <i>Journal of General Internal Medicine</i> , 2008, 23, 551-560.	1.3	92
114	Family history of completed suicide and characteristics of major depressive disorder: A STAR*D (sequenced treatment alternatives to relieve depression) study. <i>Journal of Affective Disorders</i> , 2008, 108, 129-134.	2.0	16
115	Antidepressant-associated chronic irritable dysphoria (ACID) in STEP-BD patients. <i>Journal of Affective Disorders</i> , 2008, 111, 372-377.	2.0	64
116	Brain Bioenergetics and Response to Triiodothyronine Augmentation in Major Depressive Disorder. <i>Biological Psychiatry</i> , 2008, 63, 1127-1134.	0.7	152
117	Vagus Nerve Stimulation: 2-Year Outcomes for Bipolar Versus Unipolar Treatment-Resistant Depression. <i>Biological Psychiatry</i> , 2008, 64, 455-460.	0.7	83
118	Anxiety is associated with impulsivity in bipolar disorder. <i>Journal of Anxiety Disorders</i> , 2008, 22, 868-876.	1.5	66
119	Antecedentes familiares de suicidio consumado y caracterĂsticas del trastorno depresivo mayor: estudio STAR*D (sequenced treatment alternatives to relieve depression). <i>PsiquiatrĂa BiolĂgica</i> , 2008, 15, 195-201.	0.0	0
120	Selecting Among Second-Step Antidepressant Medication Monotherapies. <i>Archives of General Psychiatry</i> , 2008, 65, 870.	13.8	152
121	Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. <i>Focus (American Psychiatric Publishing)</i> , 2008, 6, 128-142.	0.4	17
122	Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report. <i>Focus (American Psychiatric Publishing)</i> , 2008, 6, 104-119.	0.4	2
123	Major Depressive Disorder: <i>Epidemiology, Course of Illness, and Treatment</i>. <i>CNS Spectrums</i> , 2008, 13, 4-7.	0.7	4
124	A Brief Review of Antidepressant Efficacy, Effectiveness, Indications, and Usage for Major Depressive Disorder. <i>Journal of Occupational and Environmental Medicine</i> , 2008, 50, 428-436.	0.9	54
125	Clinically Relevant Findings from STAR*D. <i>Psychiatric Annals</i> , 2008, 38, .	0.1	12
126	Pharmacological Approaches to Treatment-Resistant Depression. , 2008, , 621-634.		0



#	ARTICLE	IF	CITATIONS
127	Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2007, 164, 739-752.	4.0	297
128	Predictors of Attrition During Initial (Citalopram) Treatment for Depression: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2007, 164, 1189-1197.	4.0	129
129	Effect of Age at Onset on the Course of Major Depressive Disorder. <i>American Journal of Psychiatry</i> , 2007, 164, 1539-1546.	4.0	393
130	Cognitive Behavioral Therapy for Rapid-Cycling Bipolar Disorder: A Pilot Study. <i>Journal of Psychiatric Practice</i> , 2007, 13, 291-297.	0.3	20
131	Dr. McGrath and Colleagues Reply. <i>American Journal of Psychiatry</i> , 2007, 164, 524-524.	4.0	3
132	Why Do Clinical Trials Fail?. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 1-5.	0.7	108
133	Psychosocial Treatments for Bipolar Depression. <i>Archives of General Psychiatry</i> , 2007, 64, 419.	13.8	485
134	Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. <i>Psychiatry Research</i> , 2007, 149, 195-200.	1.7	27
135	Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. <i>Current Medical Research and Opinion</i> , 2007, 23, 401-416.	0.9	127
136	A Critical Overview of the Pharmacologic Management of Treatment-Resistant Depression. <i>Psychiatric Clinics of North America</i> , 2007, 30, 13-29.	0.7	39
137	Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression. <i>New England Journal of Medicine</i> , 2007, 356, 1711-1722.	13.9	822
138	Is Psychosocial Management Effective?â€”Reply. <i>Archives of General Psychiatry</i> , 2007, 64, 1452.	13.8	0
139	Understanding the link between anxiety symptoms and suicidal ideation and behaviors in outpatients with bipolar disorder. <i>Journal of Affective Disorders</i> , 2007, 97, 91-99.	2.0	56
140	Childhood antecedent disorders to bipolar disorder in adults: A controlled study. <i>Journal of Affective Disorders</i> , 2007, 99, 51-57.	2.0	67
141	Family history of mood disorder and characteristics of major depressive disorder: A STAR*D—D (sequenced treatment alternatives to relieve depression) study. <i>Journal of Psychiatric Research</i> , 2007, 41, 214-221.	1.5	67
142	The association of comorbid anxiety disorders with suicide attempts and suicidal ideation in outpatients with bipolar disorder. <i>Journal of Psychiatric Research</i> , 2007, 41, 255-264.	1.5	155
143	Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression. <i>New England Journal of Medicine</i> , 2006, 354, 1231-1242.	13.9	934
144	An Evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: A Sequenced Treatment Alternatives to Relieve Depression Trial Report. <i>Biological Psychiatry</i> , 2006, 59, 493-501.	0.7	344

#	ARTICLE	IF	CITATIONS
145	Self-Rated Global Measure of the Frequency, Intensity, and Burden of Side Effects. <i>Journal of Psychiatric Practice</i> , 2006, 12, 71-79.	0.3	227
146	Tranlycypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2006, 163, 1531-1541.	4.0	300
147	Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. <i>British Journal of Psychiatry</i> , 2006, 189, 20-25.	1.7	188
148	Presenting characteristics of depressed outpatients as a function of recurrence: Preliminary findings from the STAR*D clinical trial. <i>Journal of Psychiatric Research</i> , 2006, 40, 59-69.	1.5	95
149	Predictors of Recurrence in Bipolar Disorder: Primary Outcomes From the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). <i>Focus (American Psychiatric Publishing)</i> , 2006, 4, 553-561.	0.4	7
150	Predictors of Recurrence in Bipolar Disorder: Primary Outcomes From the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). <i>American Journal of Psychiatry</i> , 2006, 163, 217-224.	4.0	563
151	Clinical Features of Bipolar Depression Versus Major Depressive Disorder in Large Multicenter Trials. <i>American Journal of Psychiatry</i> , 2006, 163, 225-231.	4.0	189
152	A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2006, 163, 1161-1172.	4.0	233
153	Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants. <i>Psychiatric Services</i> , 2006, 57, 660-665.	1.1	110
154	Clinical and Demographic Factors Associated With DSM-IV Melancholic Depression. <i>Annals of Clinical Psychiatry</i> , 2006, 18, 91-98.	0.6	105
155	A Comparison of Lithium and T <sub>3</sub> Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2006, 163, 1519-1530.	4.0	526
156	Treatment-Resistant Bipolar Depression: A STEP-BD Equipose Randomized Effectiveness Trial of Antidepressant Augmentation With Lamotrigine, Inositol, or Risperidone. <i>American Journal of Psychiatry</i> , 2006, 163, 210-216.	4.0	218
157	Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice. <i>American Journal of Psychiatry</i> , 2006, 163, 28-40.	4.0	3,206
158	Medication Augmentation after the Failure of SSRIs for Depression. <i>New England Journal of Medicine</i> , 2006, 354, 1243-1252.	13.9	897
159	Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2006, 163, 1905-1917.	4.0	4,241
160	A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. <i>American Journal of Psychiatry</i> , 2006, 163, 1161-72.	4.0	167
161	Factors Associated With Health-Related Quality of Life Among Outpatients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 185-195.	1.1	139
162	The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 523.	1.0	81

#	ARTICLE	IF	CITATIONS
163	A Double-blind, Randomized Trial of St John's Wort, Fluoxetine, and Placebo in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 441-447.	0.7	116
164	Empirical Testing of Two Models for Staging Antidepressant Treatment Resistance. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 336-341.	0.7	96
165	Panic disorder and bipolar disorder: Anxiety sensitivity as a potential mediator of panic during manic states. <i>Journal of Affective Disorders</i> , 2005, 87, 101-105.	2.0	31
166	Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II). <i>Psychiatry Research - Neuroimaging</i> , 2005, 140, 301-307.	0.9	35
167	A Description of Next-Step Switching Versus Augmentation Practices for Outpatients with Treatment-Resistant Major Depressive Disorder Enrolled in an Academic Specialty Clinic. <i>Annals of Clinical Psychiatry</i> , 2005, 17, 161-165.	0.6	12
168	Serotonin gene polymorphisms and bipolar I disorder: Focus on the serotonin transporter. <i>Annals of Medicine</i> , 2005, 37, 590-602.	1.5	39
169	Industry Sponsorship and Financial Conflict of Interest in the Reporting of Clinical Trials in Psychiatry. <i>American Journal of Psychiatry</i> , 2005, 162, 1957-1960.	4.0	288
170	Clinical and Diagnostic Implications of Lifetime Attention-Deficit/Hyperactivity Disorder Comorbidity in Adults with Bipolar Disorder: Data from the First 1000 STEP-BD Participants. <i>Biological Psychiatry</i> , 2005, 57, 1467-1473.	0.7	247
171	Vagus Nerve Stimulation for Treatment-Resistant Depression: A Randomized, Controlled Acute Phase Trial. <i>Biological Psychiatry</i> , 2005, 58, 347-354.	0.7	542
172	Psychopathology in the Offspring of Parents with Bipolar Disorder: A Controlled Study. <i>Biological Psychiatry</i> , 2005, 58, 554-561.	0.7	175
173	Revisiting Depressive-Prone Bipolar Disorder: Polarity of Initial Mood Episode and Disease Course Among Bipolar I Systematic Treatment Enhancement Program for Bipolar Disorder Participants. <i>Biological Psychiatry</i> , 2005, 58, 549-553.	0.7	82
174	Does Recovery From Substance Use Disorder Matter in Patients With Bipolar Disorder?. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 730-735.	1.1	111
175	Clinical and Demographic Features of Atypical Depression in Outpatients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1002-1011.	1.1	165
176	An Open Study of Triiodothyronine Augmentation of Selective Serotonin Reuptake Inhibitors in Treatment-Resistant Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1038-1042.	1.1	53
177	Anxiety Disorder Comorbidity in Bipolar Disorder Patients: Data From the First 500 Participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). <i>American Journal of Psychiatry</i> , 2004, 161, 2222-2229.	4.0	501
178	Suicide risk management for the sequenced treatment alternatives to relieve depression study: applied NIMH guidelines. <i>Journal of Psychiatric Research</i> , 2004, 38, 583-589.	1.5	25
179	The prevalence and clinical correlates of anger attacks during depressive episodes in bipolar disorder. <i>Journal of Affective Disorders</i> , 2004, 79, 291-295.	2.0	82
180	Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. <i>Contemporary Clinical Trials</i> , 2004, 25, 119-142.	2.0	898

#	ARTICLE	IF	CITATIONS
181	Quality of life assessments in major depressive disorder: a review of the literature. <i>General Hospital Psychiatry</i> , 2004, 26, 13-17.	1.2	245
182	Long-Term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). <i>Biological Psychiatry</i> , 2004, 55, 875-881.	0.7	746
183	Effect of Medical Comorbidity on Response to Fluoxetine Augmentation or Dose Increase in Outpatients With Treatment-Resistant Depression. <i>Psychosomatics</i> , 2004, 45, 224-229.	2.5	25
184	Psychosocial Functioning During the Treatment of Major Depressive Disorder With Fluoxetine. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 507-511.	0.7	57
185	Pharmacotherapy for Bipolar Disorder and Comorbid Conditions. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 512-520.	0.7	97
186	S-Adenosyl-L-Methionine (SAMe) as an Adjunct for Resistant Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 661-664.	0.7	97
187	Illness Beliefs of Depressed Chinese American Patients in Primary Care. <i>Journal of Nervous and Mental Disease</i> , 2004, 192, 324-327.	0.5	87
188	Presence of Irritability During Depressive Episodes in Bipolar Disorder. <i>CNS Spectrums</i> , 2004, 9, 227-231.	0.7	33
189	Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. <i>Psychiatric Clinics of North America</i> , 2003, 26, 457-494.	0.7	456
190	Predictors of response to antidepressants. <i>Psychiatric Clinics of North America</i> , 2003, 26, 345-352.	0.7	78
191	Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). <i>Biological Psychiatry</i> , 2003, 53, 1028-1042.	0.7	493
192	Axis III disorders in treatment-resistant major depressive disorder. <i>Psychiatry Research</i> , 2003, 118, 183-188.	1.7	26
193	Serum Cholesterol in Treatment-Resistant Depression. <i>Neuropsychobiology</i> , 2003, 47, 146-151.	0.9	41
194	Behavioral and Emotional Disturbances in the Offspring of Depressed Parents with Anger Attacks. <i>Psychotherapy and Psychosomatics</i> , 2003, 72, 102-106.	4.0	20
195	Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for treatment of major depression. <i>Journal of Neurosurgery</i> , 2003, 99, 1010-1017.	0.9	181
196	The Impact of Medical Comorbidity on Acute Treatment in Major Depressive Disorder. <i>American Journal of Psychiatry</i> , 2003, 160, 2122-2127.	4.0	109
197	Assay Sensitivity, Failed Clinical Trials, and the Conduct of Science. <i>Psychotherapy and Psychosomatics</i> , 2002, 71, 241-243.	4.0	46
198	Effects of Adding Cognitive Therapy to Fluoxetine Dose Increase on Risk of Relapse and Residual Depressive Symptoms in Continuation Treatment of Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 474-480.	0.7	63

#	ARTICLE	IF	CITATIONS
199	USE OF THE CHINESE VERSION OF THE BECK DEPRESSION INVENTORY FOR SCREENING DEPRESSION IN PRIMARY CARE. <i>Journal of Nervous and Mental Disease</i> , 2002, 190, 94-99.	0.5	72
200	Magnetic Resonance Imaging-guided Stereotactic Limbic Leukotomy for Treatment of Intractable Psychiatric Disease. <i>Neurosurgery</i> , 2002, 50, 1043-1052.	0.6	74
201	Prospective Long-Term Follow-Up of 44 Patients Who Received Cingulotomy for Treatment-Refractory Obsessive-Compulsive Disorder. <i>American Journal of Psychiatry</i> , 2002, 159, 269-275.	4.0	310
202	Magnetic Resonance Imaging-guided Stereotactic Limbic Leukotomy for Treatment of Intractable Psychiatric Disease. <i>Neurosurgery</i> , 2002, 50, 1043-1052.	0.6	64
203	A survey of prescribing practices in the treatment of depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2002, 26, 177-187.	2.5	62
204	Strategies for Treatment of SSRI-Associated Sexual Dysfunction: A Survey of an Academic Psychopharmacology Practice. <i>Harvard Review of Psychiatry</i> , 2002, 10, 109-114.	0.9	15
205	Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. <i>Annals of Clinical Psychiatry</i> , 2002, 14, 33-8.	0.6	44
206	Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for obsessive compulsive disorder. <i>Biological Psychiatry</i> , 2001, 50, 659-667.	0.7	133
207	Psychiatric comorbidity in treatment-resistant depression. , 2001, , 430-478.		2
208	T3 Blood Levels and Treatment Outcome in Depression. <i>International Journal of Psychiatry in Medicine</i> , 2001, 31, 367-373.	0.8	12
209	Timing of Onset of Antidepressant Response With Fluoxetine Treatment. <i>American Journal of Psychiatry</i> , 2000, 157, 1423-1428.	4.0	207
210	Volumetric reduction in caudate nucleus following stereotactic lesions of anterior cingulate cortex in humans: a morphometric magnetic resonance imaging study. <i>Journal of Neurosurgery</i> , 2000, 93, 1019-1025.	0.9	98
211	Partial Response, Nonresponse, and Relapse With Selective Serotonin Reuptake Inhibitors in Major Depression. <i>Journal of Clinical Psychiatry</i> , 2000, 61, 403-408.	1.1	117
212	Patterns of axis I comorbidity in early-onset versus late-onset major depressive disorder. <i>Biological Psychiatry</i> , 1999, 46, 202-211.	0.7	62
213	Mania associated with St. John's wort. <i>Biological Psychiatry</i> , 1999, 46, 1707-1708.	0.7	88
214	Compounds Containing Cytosolic Choline in the Basal Ganglia: A Potential Biological Marker of True Drug Response to Fluoxetine. <i>American Journal of Psychiatry</i> , 1999, 156, 1638-1640.	4.0	61
215	Open Study of the Catechol-O-Methyltransferase Inhibitor Tolcapone in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 1999, 19, 329-335.	0.7	51
216	The Texas Medication Algorithm Project. <i>Journal of Clinical Psychiatry</i> , 1999, 60, 142-156.	1.1	174

#	ARTICLE	IF	CITATIONS
217	Residual Symptoms in Depressed Patients Who Respond Acutely to Fluoxetine. <i>Journal of Clinical Psychiatry</i> , 1999, 60, 221-225.	1.1	395
218	An Open Trial of Oral Sildenafil Antidepressant-Induced Sexual Dysfunction. <i>Psychotherapy and Psychosomatics</i> , 1998, 67, 328-331.	4.0	117
219	Outcome Definitions and Predictors in Depression. <i>Psychotherapy and Psychosomatics</i> , 1998, 67, 266-270.	4.0	75
220	Emergence of Adverse Events Following Discontinuation of Treatment With Extended-Release Venlafaxine. <i>American Journal of Psychiatry</i> , 1997, 154, 1760-1762.	4.0	167
221	Basal ganglia choline levels in depression and response to fluoxetine treatment: An in vivo proton magnetic resonance spectroscopy study. <i>Biological Psychiatry</i> , 1997, 41, 837-843.	0.7	107
222	Major depressive subtypes and treatment response. <i>Biological Psychiatry</i> , 1997, 42, 568-576.	0.7	222
223	Attention deficit hyperactivity disorder in childhood among adults with major depression. <i>Psychiatry Research</i> , 1996, 62, 213-219.	1.7	107
224	Discontinuation reactions following sertraline. <i>Biological Psychiatry</i> , 1995, 38, 694-695.	0.7	25
225	Venlafaxine for Treatment-Resistant Unipolar Depression. <i>Journal of Clinical Psychopharmacology</i> , 1994, 14, 419-423.	0.7	160
226	Evidence-based pharmacotherapy of major depressive disorder. , 0, , 53-72.		0